LONG MINI-FUTURE - ROCHE GS Stock

Certificat

DE000VN42WM5

Real-time Bid/Ask 08:17:51 2024-05-02 EDT
2.38 EUR / 2.39 EUR -10.00% Intraday chart for LONG MINI-FUTURE - ROCHE GS
1 month-19.45%
3 months-47.00%
Date Price Change Volume
24-05-02 2.56 -3.40% 0
24-04-30 2.65 -2.21% 0
24-04-29 2.71 +7.11% 0
24-04-26 2.53 -6.99% 0
24-04-25 2.72 -23.38% 0

Delayed Quote Börse Stuttgart

Last update May 02, 2024 at 02:27 am

More quotes

Static data

Product typeKnock-Out mit Stop Loss
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VN42WM
ISINDE000VN42WM5
Date issued 2016-10-28
Strike 195.1 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 3.05
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 20.51
Lowest since issue 1.35
Spread 0.01
Spread %0.40%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
220.6 CHF
Average target price
279.4 CHF
Spread / Average Target
+26.65%
Consensus